The Next Set of COVID-19 Vaccines: Leveraging New Development Platforms to Increase Access for More People Around the World.
Clin Ther
; 43(4): 702-710, 2021 04.
Article
in English
| MEDLINE | ID: covidwho-1349420
ABSTRACT
The approval of the coronavirus disease 2019 (COVID-19) mRNA vaccines brought much optimism to efforts to end the pandemic. A recombinant adenovirus vaccine recently received emergency use authorization, and several other vaccines are likely to follow. These vaccines all use relatively new vaccine production platforms to produce the severe acute respiratory syndrome coronavirus 2 Spike protein. This review discusses how these platforms work, what advantages they offer, and the gaps that remain in public health efforts to control the COVID-19 pandemic. (Clin Ther. 2021;43702-710) © 2021 Elsevier HS Journals, Inc.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Spike Glycoprotein, Coronavirus
/
COVID-19 Vaccines
/
COVID-19
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Clin Ther
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS